Spots Global Cancer Trial Database for who grade 3 glioma

Every month we try and update this database with for who grade 3 glioma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy	NCT04650204	Intractable Epi... Malignant Gliom... Seizure Disorde... WHO Grade 2 Gli... WHO Grade 3 Gli...	Anticonvulsant ... Perampanel Quality-of-Life... Questionnaire A...	18 Years -	Mayo Clinic
Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas	NCT02323880	Malignant Gliom... Recurrent Brain... Recurrent Child... Recurrent Child... Recurrent Lymph... Recurrent Malig... Refractory Lymp... Refractory Mali... Refractory Prim... WHO Grade 3 Gli...	Pharmacological... Selinexor	12 Months - 21 Years	Children's Oncology Group
Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations	NCT03212274	Advanced Malign... Glioblastoma Recurrent Chola... Recurrent Gliom... Recurrent Malig... WHO Grade 2 Gli... WHO Grade 3 Gli...	Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Olaparib	18 Years -	National Cancer Institute (NCI)
Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas	NCT02323880	Malignant Gliom... Recurrent Brain... Recurrent Child... Recurrent Child... Recurrent Lymph... Recurrent Malig... Refractory Lymp... Refractory Mali... Refractory Prim... WHO Grade 3 Gli...	Pharmacological... Selinexor	12 Months - 21 Years	Children's Oncology Group
Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas	NCT02323880	Malignant Gliom... Recurrent Brain... Recurrent Child... Recurrent Child... Recurrent Lymph... Recurrent Malig... Refractory Lymp... Refractory Mali... Refractory Prim... WHO Grade 3 Gli...	Pharmacological... Selinexor	12 Months - 21 Years	Children's Oncology Group
Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy	NCT04650204	Intractable Epi... Malignant Gliom... Seizure Disorde... WHO Grade 2 Gli... WHO Grade 3 Gli...	Anticonvulsant ... Perampanel Quality-of-Life... Questionnaire A...	18 Years -	Mayo Clinic
Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy	NCT04650204	Intractable Epi... Malignant Gliom... Seizure Disorde... WHO Grade 2 Gli... WHO Grade 3 Gli...	Anticonvulsant ... Perampanel Quality-of-Life... Questionnaire A...	18 Years -	Mayo Clinic
Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma	NCT03919071	Anaplastic Astr... Anaplastic Astr... Anaplastic Gang... Anaplastic Pleo... Glioblastoma Malignant Gliom... WHO Grade 3 Gli...	Biospecimen Col... Dabrafenib Mesy... Lumbar Puncture Magnetic Resona... Radiation Thera... Trametinib Dime...	12 Months - 21 Years	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: